A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
is difficult to measure experimentally; usually, the adsorbate is a gas and the quantity adsorbed is given in moles, grams, or gas volumes at standard temperature and pressure (STP) per gram of adsorbent. If we call vmon the STP volume of adsorbate required to form a monolayer on the adsorbent (per gram of adsorbent), then
Roeder and Robert Tjian, for their outstanding work on eukaryotic transcription regulation 1993 James E. Rothman and Randy Schekman, for determining the components of the secretory pathway 1992 Paul Nurse and Leland H. Hartwell, for establishing the details of the control of eukaryotic cell cycle 1991 David Botstein, Raymond L. White and Ronald W. Davis, for creating the methods by which variations in the human genome can be detected and analyzed 1990 Richard Henderson and Peter Nigel Tripp Unwin, for determining the first structure of an integral membrane protein 1989 Christiane Nüsslein-Volhard and Edward B. Lewis, for pioneering studies of eukaryotic development 1988 Sidney Altman and Thomas R. Cech, for discovering RNA catalysis 1987 Shinya Inoué, for his innovations in light microscopy 1986 Harland G. Wood, for his outstanding work on enzyme function 1985 Seymour Benzer and Sydney Brenner, for founding modern eukaryotic genetics 1984 Donald D. Brown and Robert L. Letsinger, for their seminal work on development 1983 Eric R. Kandel and Daniel E. Koshland, Jr., for pioneering contributions to sensory transduction 1982 Keith R. Porter and Alexander Rich 1981 Stanley Cohen, Rita Levi-Montalcini and Gordon H. Sato 1980 Elias J. Corey, Bengt I. Samuelsson and Frank H. Westheimer 1979 Howard Green and Beatrice Mintz 1978 César Milstein 1977 Barbara McClintock 1976 Peter D. Mitchell 1975 Bruce Ames, James A. Miller and Elizabeth C. Miller 1974 Arthur B. Pardee and H. Edwin Umbarger 1973 H. Ronald Kaback and Saul Roseman 1972 Boris Ephrussi 1971 David H. Hubel and Torsten N.
==== Brown MX-5BR ==== Brown MX-5BR or Reactive Brown 10 has a formula of C40H19Cl4CrN12Na2O12S2 and a molecular weight of 1163.6 g/mol, containing two dichlorotriazine rings. Brown MX-5BR, for example, can be used to purify lysozyme, phosphinothricin acetyltransferase. It also shown that it can elute tryptophanyl-tRNA synthetase using Trp as eluant, however, tryptophanyl-tRNA and tyrosyl-tRNA synthetase are the only t-RNA that can be elute out using Brown MX-5BR.
=== 'Bronze Age' BioBlitz === On 2 August 2014, a BioBlitz organised by Vivacity found 190 species, including 53 lichens and the endangered European water vole and barn owl. The event also included a talk by the People's Trust for Endangered Species and used a wildlife trail to highlight species that would have been present 3,000 years ago, such as the grey wolf, brown bear and Eurasian beaver.
=== Screening for cardiometabolic issues === Given the higher risk of cardiometabolic conditions, monitoring is recommended. This includes testing of glucose tolerance, using a two-hour oral glucose tolerance test (GTT) in all women with PMOS. After initial testing at diagnosis, follow-up assessments are advised every one to three years, depending on the presence of diabetes risk factors. Screening for cardiovascular risk factors includes lipid profile tests and yearly blood pressure measurements.
Sources: en.wikipedia.org
=== Performance === The theme that structures the novel is that of performance. As the book opens, Kaname is gently pressuring his wife, Misako, into meeting her father and his mistress at a bunraku performance. The "old man" (he is fifty-six or fifty-seven) has a deep interest in many forms of traditional Japanese performance, from samisen and song to rustic puppets. But these are only the framing performances, as the life being led by Kaname and Misako is itself a performance, as Tanizaki reminds us several times. Even their son, Hiroshi, becomes a performer. The closing words of the novel transform a wooden doll into a woman. In many ways, from local accent to clothing, the central characters assume roles they need and can hardly bear, making the story a series of mirrors in which artifice and reality become interwoven.
==== United States ==== As of 2018, Zipline was working with the FAA to develop rules for drone operation beyond the line of sight. During the COVID-19 pandemic in 2020, the FAA granted a Part 107 waiver to Novant Health in partnership with Zipline for the delivery of medical supplies and personal protective equipment to facilities in North Carolina. The company plans to offer deliveries to homes. On November 18, 2021, Zipline started a trial service with Walmart for e-commerce shopping deliveries in Pea Ridge, Arkansas. The service, selectable to online shoppers using a special mobile app, could deliver to all residences within 50 miles (80 km) of a particular Walmart store in Pea Ridge during daylight hours. On June 21, 2022, the license "Package Delivery by Drone (Part 135)" was granted. On October 4, 2022, Zipline began commercial delivery services in Salt Lake City, Utah, in partnership with Intermountain Healthcare. On September 18, 2023, the FAA announced it had authorized Zipline to begin making commercial deliveries beyond the line of sight without visual observers. In April 2025, Zipline began making deliveries for Walmart in the Dallas–Fort Worth metroplex using Platform 2 drones.
In the pancreas, osteocalcin acts on beta cells, causing beta cells in the pancreas to release more insulin. In fat cells, osteocalcin triggers the release of the adiponectin hormone, which increases insulin sensitivity. In muscle, osteocalcin acts on myocytes to promote energy availability and utilization and, in this manner, favors exercise capacity. In the testes, osteocalcin acts on Leydig cells, stimulating testosterone biosynthesis and affecting male fertility. In the brain, osteocalcin plays an important role in development and functioning, including spatial learning and memory. An acute stress response (ASR), colloquially known as the fight-or-flight response, stimulates osteocalcin release from bone within minutes in mice, rats, and humans. Injections of high levels of osteocalcin alone can trigger an ASR in the presence of adrenal insufficiency.
== Safety and toxicity == Excess pre‑formed vitamin A from supplements or fortified foods can cause hypervitaminosis A, characterized acutely by nausea and raised intracranial pressure and chronically by liver injury and teratogenicity. Retinyl acetate shares these dose‑dependent toxicities because it is quantitatively hydrolyzed to retinol. Phototoxicity and photo‑isomerization are significantly lower than for unesterified retinol but can occur in formulations lacking UV stabilizers.
=== Preclinical safety data === Conventional long-term toxicity, reproduction, mutagenicity, and carcinogenicity studies have been performed in laboratory animals. Salmon calcitonin is devoid of embryotoxic, teratogenic, and mutagenic potential. An increased incidence of pituitary adenomas has been reported in rats given synthetic salmon calcitonin for 1 year. This is considered a species-specific effect and of no clinical relevance. Salmon calcitonin does not cross the placental barrier. In lactating animals given calcitonin, suppression of milk production has been observed. Calcitonin is secreted into the milk.
Sources: en.wikipedia.org
This led to a major restructuring of human societies from nomadic to sedentary, with more co-operation among larger and larger groups, and ultimately the development of the first civilizations. Domesticated mammals provided, and continue to provide, power for transport and agriculture, as well as food (meat and dairy products), fur, and leather. Mammals are also hunted and raced for sport, kept as pets and working animals of various types, and are used as model organisms in science. Mammals have been depicted in art since Paleolithic times, and appear in literature, film, mythology, and religion. The decline in numbers and extinction of many mammals is primarily driven by human poaching and habitat destruction, primarily deforestation.
=== Broadcasting === While attending college in Drury, Barker worked his first media job at KTTS-FM Radio in Springfield. He and his wife left Springfield and moved to Lake Worth Beach, Florida, and Barker was news editor and announcer at nearby WWPG 1340 AM in Palm Beach (now WPBR in Lantana). In 1950, he moved to California to advance his broadcasting career. Barker was given his own radio show, The Bob Barker Show, which ran for the next six years from Burbank. He was hosting an audience-participation radio show on KHJ (AM) in Los Angeles when game show producer Ralph Edwards, who was looking for a new host to replace Jack Bailey on the daytime-television version of his long-running show, Truth or Consequences, happened to be listening and liked Barker's voice and style.
It was expected that uranium would be scarce and high-grade deposits would quickly become depleted if fission power were deployed on a large scale; the reality, however, is that since the end of the Cold War, uranium has been much cheaper and more abundant than early designers expected. Breeder reactors were expected to become economically competitive with light-water reactors. In 2010, Thomas B. Cochran and colleagues reported that demonstration sodium-cooled fast reactors had typically cost more than twice as much per kilowatt of generating capacity as similarly sized water-cooled reactors. They noted that this cost gap might narrow with production, but wrote that few experts anticipated a capital-cost premium below 25%. It was thought that breeder reactors could be as safe and reliable as light-water reactors, but safety issues are cited as a concern with fast reactors that use a sodium coolant, where a leak could lead to a sodium fire. It was expected that the proliferation risks posed by breeders and their "closed" fuel cycle, in which plutonium would be recycled, could be managed. But since plutonium-breeding reactors produce plutonium from U238, and thorium reactors produce fissile U233 from thorium, all breeding cycles could theoretically pose proliferation risks. However U-232, which is always present in U-233 produced in breeder reactors, is a strong gamma-emitter via its daughter products, and would make weapon handling extremely hazardous and the weapon easy to detect.
γ-Butyrolactone (GBL) or gamma-butyrolactone is an organic compound with the formula O=CO(CH2)3. It is a hygroscopic, colorless, water-miscible liquid with a pleasant odor. It is the simplest 4-carbon lactone. It is mainly used as an intermediate in the production of other chemicals, such as N-methyl-2-pyrrolidone. In humans, GBL acts as a prodrug for gamma-hydroxybutyric acid (GHB) and is often used as a recreational drug. GHB acts as a central nervous system (CNS) depressant with effects similar to those of barbiturates.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.